Racemic mexiletine is a widely used antiarrhythmic agent which blocks sodium channels. The effects of R-(-) and S-(+) mexiletine stereoisomers on maximum rate of depolarization (Vmax), conduction time and repolarization have not yet been investigated in isolated cardiac preparations. We studied the effect of the R-(-) and S-(+) mexiletine on rabbit cardiac action potential parameters by using the conventional microelectrode technique. Both enantiomers at 20 µM of therapeutically and experimentally relevant concentration, significantly depressed the Vmax at fast heart rates (BCLs 300 -700 ms). R-(-) mexiletine has more potent inhibitory effect than S-(+) mexiletine. Both R-(-) and S-(+) mexiletine significantly inhibited the Vmax of early extrasystoles measured at 70 ms diastolic interval induced by S1-S2 stimuli. R-(-) mexiletine has more pronounced inhibitory effect than S-(+) mexiletine. Both R-(-) and S-(+) mexiletine increased significantly the ERP/APD 90 ratio. The time constant (τ) of recovery of Vmax was found to be τ = 376.0 ± 77.8 ms for R-(-) mexiletine and τ = 227.1 ± 23.4 ms for S-(+) mexiletine which indicates a slower offset kinetics for R-(-) mexiletine from sodium channels than that of the S-(+) enantiomer. These data suggest that R-(-) mexiletine might be more potent antiarrhythmic agent than S-(+) mexiletine.
Introduction
The compound Kö 1173, later denominated mexiletine, exerted anticonvulsant activity in animal experiments. Since 1972 mexiletine has been recognized as an antiarrhythmic agent with characteristics similar to those of lidocaine (Vaughan Williams 1998) . The racemic mexiletine had been classified as a Class 1b antiarrhythmic compound (Vaughan Williams 1998) , which blocks sodium channels in a use dependent manner with relatively fast onset and offset kinetics of Vmax block (Campbell 1983; Varró et al. 1985) . The most important advantage of mexiletine over lidocaine is its good oral availability and longer half-life.
Mexiletine reduces use-dependently the magnitude of fast sodium current (Hering et al. 1983 ), markedly slows premature conduction (Hohnloser et al. 1982) , suppresses abnormal automacity in Purkinje fibers (Sarkozy and Dorian 2007) and shortens the durations of action potentials (Arita et al. 1979; Yamaguchi et al. 1979) . The main cardiac indication of mexiletine is the treatment of ventricular arrhythmias (Mason 1993; Singh et al. 1990 ). At present, there is a need for available pharmacotherapy to target directly the ionic basis of most long QT syndromes (LQTS) for the acute termination of torsades de pointes (TdP) arrhythmia. In a recent article it has been reported that mexiletine may be an effective treatment approach to terminate refractory TdP from several acquired causes of LQTS (Badri et al. 2015) . Mexiletine is applied in extracardiac disorders, too. It is widely administered in the therapy of myotonic disorders (Logigian et al. 2010; Statland et al. 2012) , in Timothy syndrome (Gao Y. et al. 2013) , in neuropathies (O'Connor and Dworkin 2009) and in chronic pain (Park and Moon 2010) . A recent study (Weiss et al. 2016) have provided Class I evidence that mexiletine has been safe when given daily to patients with amyotrophic lateral sclerosis (ALS). Mexiletine therapy has resulted in large dose-dependent decreases in muscle cramp frequency and severity. The racemic mexiletine preparations containing both isomers stereoselective effects of mexiletine enantiomers on sodium currents and excitability of skeletal muscle fibers (De Luca et al. 1995) . They found that R-(-) isomers were more potent in sodium current blockade and they highlighted the probable usefulness of low doses of R-(-) mexiletine in the therapy of the abnormal hyperexcitability of the myotonic muscles, with an expectable reduction of unwanted side effects. However, the detailed cardiac electrophysiological effects of the R-(-) and S-(+) mexiletine isomers on cardiac ventricular preparations have not been investigated yet. We examined whether a significant difference exists between the cardiac electrophysiological effects of the two enantiomers. Our research group analysed the effects of the enantiomers on action potential parameters in different protocols performed on rabbit right ventricular papillary muscle preparations. The main findings of our study are that the R-(-) mexiletine displays slower offset kinetics than S-(+) mexiletine, and R-(-) mexiletine displays a tendency to more potent inhibitory effect than S-(+) mexiletine on Vmax, especially at early premature action potentials, i. During the equilibration period, the ventricular muscle tissues were stimulated at a basic cycle length of 1000 ms. Electrical pulses of 2 ms in duration and twice diastolic threshold in intensity (S1) were delivered to the preparations through bipolar platinum electrodes.
Transmembrane potentials were recorded with the use of glass capillary microelectrodes filled with 3 M KCl (tip resistance: 5 to 15 MΩ). The microelectrodes were coupled through an AgAgCl junction to the input of a high impedance, capacitance-neutralizing amplifier (Experimetria 2004) . Intracellular recordings were displayed on a storage oscilloscope (Hitachi V-555) and led to a computer system (APES) designed for online determination of the following parameters: resting membrane potential, action potential amplitude, action potential duration at 10%, 25%, 50% and 90% repolarization and the maximum rate of rise of the action potential upstroke (Vmax). The following types of stimulation were applied in the course of the experiments: stimulation with a constant cycle length of 1000 ms (ventricular muscles); stimulation with different constant cycle lengths ranging from 300 to 5000 ms. In order to establish the recovery of Vmax, extra test action potentials were elicited by using D r a f t 6 single test pulses (S 2 ) in a preparation driven at a basic cycle length of 1000 ms (S 1 ). The S 1 -S 2 interval was gradually increased from the end of refractory period. The action potential characteristics of the potentials evoked by each S 2 were determined. The diastolic interval preceding the test action potential was measured from the point corresponding to 90%
repolarization of the preceding basic action potential to delivery of S 2 . The effective refractory period (ERP) of the preparation, defined as the shortest S1-S2 interval that evoked a propagated action potential using a stimulus amplitude equal to twice the diastolic threshold intensity, was also determined. Once control measurements had been obtained, the preparation was superfused either for 45 min with 20 µM R-(-) mexiletine or S-(+) mexiletine.
The therapeutically and experimentally relevant concentration of mexiletine amounts to about 20 µM (Paalman et al. 1977) . Same concentration was applied at both stereoisomers.
Following these periods of exposure, all action potential parameters were again obtained.
Statistical analysis
Statistical differences were evaluated with Student's t-test and differences were considered significant when p<0.05. Data are expressed as mean ± S.E.M. (standard error of the mean).
D r a f t
Results

Effects of mexiletine enantiomers on transmembrane action potentials
The effects of 20 µM R-(-) and S-(+) enantiomers of mexiletine on action potential characteristics in rabbit ventricular/papillary muscle preparations are summarized in Table 1, with examples illustrated in Figure 1 . At a stimulation cycle length of 1000 ms the enantiomers did not change ventricular repolarization (Table 1 and Figure 1 ). Neither R-(-)
nor S-(+) mexiletine had effects on the action potential amplitude, the maximal diastolic potential/membrane resting potential. Both R-(-) and S-(+) mexiletine significantly increased the ERP/APD 90 ratio (Table 1) . Both enantiomers at 20 µM concentration significantly depressed the Vmax (Table 1) Table 2 . Both R-(-) and S-(+) mexiletine significantly depressed the Vmax (Table 2) 
Possible mechanisms
Mexiletine which is a widely used antiarrhythmic drug exists as a racemic mixture i.e. the available drug preparations contain both S-(+) and R-(-) enantiomers. It has been extensively studied and established that racemic mexiletine inhibits Vmax in different cardiac preparations with relatively fast recovery like lidocaine and as such it was classified as class IB antiarrhythmic drug (Campbell 1983; Varró et al. 1985) . Although the enantiomers, like with sotalol, may have different effect, so far the cellular cardiac electrophysiological effect of the S-(+) and R-(-) enantiomers have never been studied and analysed. Therefore we have studied the cardiac electrophysiological effects of mexiletine enantiomers (20 µM) on isolated rabbit ventricular preparations. In order to establish whether the R-(-) and S-(+) enantiomers had different property, we first examined the effect of the stereoisomers on Vmax, which is the maximum rising velocity of the action potential upstroke. Vmax measurements are indicative for I Na function (i.e.: cycle length dependent Vmax block in rabbit ventricular muscles is attributable to the inhibitory effect of mexiletine enantiomers on the fast Na + current, but cannot be applied for quantitative estimation of sodium channel availability, which could be underestimated by such measurements (Sheets et al. 1998) , since Vmax can be considered as a nonlinear indicator of the fast inward sodium current (Cohen et al. 1984) .
We have found that both the R-(-) and S-(+) enantiomers of mexiletine at 20 µM produced a rate-dependent inhibition of the Vmax value (Figures 2A, 2B ), but the inhibition was more pronounced in the case of the R-(-) mexiletine ( Figure 2C ). The stronger depression of Vmax by the R-(-) enantiomer can be attributed to the slower offset kinetics comparing to its S-(+)
enantiomer. Indeed, at cycle length range of 400-1000 ms the R-(-) enantiomer caused more pronounced Vmax depression than the S-(+) one. R-(-) mexiletine suppressed Vmax of early premature action potentials significantly (Table 2) , and this inhibition was also more D r a f t pronounced than that of S-(+) mexiletine. Therefore we can speculate that application of medications containig only the R-(-) mexiletine might decrease the probability of a second conducted impulse occurring at short premature intervals and thereby reduces the possibility of developing re-entrant tachyarrhythmias. De Luca et al. demonstrated the stereoselective effects of mexiletine enantiomers (tested at 50 and 100 µM) on sodium currents and excitability of frog skeletal muscle fibers. They found that R-(-) isomers were more potent in sodium current blockade. Inhibition of sodium current has been found to be more pronounced when the resting membrane potential is partly depolarized (Pu et al. 1998) e.g. in ischaemic tissues. Therefore the stereoselective effect of mexiletine isomers on Vmax , what we have found , could be further investigated in future experiments in cardiac preparations exposed to in vitro ischemia protocols, mimicking ischemic heart diseases. We also measured another important parameter reflecting the availability of sodium channels, next to Vmax, the impulse conduction time (CT). Before administration of each enantiomer, impulse conduction time was independent of the stimulation cycle length (300-5000 msec, Figure 3 ). Both enantiomers were capable of exerting marked rate-dependent impulse conduction time (CT) changes 
Clinical implications
A retrospective study ) performed on patients with an implantable cardioverter defibrillator (ICD) revealed that when mexiletine was added to amiodarone in case of amiodarone ineffectiveness, the combination of these drugs reduced ventricular tachycardia/fibrillation events which might mean appropriate therapy in these patients. In an D r a f t other retrospective study it has recently been demonstrated (Mazzanti et al. 2016 ) that longterm treatment with mexiletine shortened the QT interval and resulted in a major reduction of life-threatening arrhythmic events in LQT3 patients. Another recent study (Badri et al. 2015) concluded that in patients with acquired LQT and torsades de pointes refractory to conventional treatments, the application of mexiletine may be considered. Giving possible cellular cardiac electrophysiological explanations for the latter observations we should note that many years ago mexiletine was found to be able to abbreviate the APD of the M cells and to suppress the development of EADs (Sicouri et al. 1997 ) and was also found to be highly effective in decreasing dispersion of repolarization and preventing torsade des pointes in difference between mexiletine stereoisomers in 12 healthy human subjects. In their study (Kwok et al. 1995) it was described that after oral administration of 200 mg racemic mexiletine: the mean serum total R-(-) mexiletine concentrations were significantly higher than those for S-(+) mexiletine during the first 6 hours following drug administration. It was found in a human study (McErlane et al. 1987 ) involving five healthy subjects that the serum protein binding was significantly greater for R-(-) mexiletine than its antipode and the free fraction of S-(+) mexiletine was 28.32 ± 1.45% and that of the R-(-) enantiomer was 19.80 ± 1.49%. Another study (Igwemezie et al. 1989 ) involving five healthy subjects revealed that the elimination half-life of S-(+) mexiletine was 11.0 +/-3.80 h, which was significantly longer than that of the R-(-) enantiomer, 9.10 +/-2.90 h. A study (Mehvar et al. 2002) in rats uncovered non stereoselective distribution of the isomers to most tissues with the exception of the liver, where the concentration of the S-(+) stereoisomer was more than twice of that of its antipode. This study also established a 2-fold higher tissue/serum concentration ratio for S-(+) mexiletine enantiomer as compared with the ratio for the R-(-) isomer. The most frequently seen adverse effects of mexiletine are often dose related and they affect mainly the central nervous system. Tremors, nystagmus, blurred vision, dizziness, drowsiness, confusion, ataxia, paresthesia, dysarthria, insomnia, tinnitus and convulsions are the most common side effects.
Gastrointestinal disturbances can also develop during mexiletine therapy (Vaughan Williams 1998) . Detailed studies are still needed to establish the pharmacokinetic difference between the two stereoisomers and its possible therapeutic and toxicological significance. 
